UiPath's 24% Post-Earnings Plunge: Growth Quality Questioned Despite Beat

What happened

UiPath reported Q2 FY27 results that beat revenue expectations and raised full-year profitability guidance, yet shares fell 24% immediately after. The steep sell-off indicates investors focused on forward-looking metrics—likely ARR growth, net-new ARR, or net revenue retention—that missed the company's own or market's expectations, conflicting with the headline beat. Prior DeepValue analysis had flagged these exact metrics as thesis-critical: ARR guide $1.929B–$1.934B, NRR≥108%, and net-new ARR≥$40M; any shortfall would weaken the investment case. The post-earnings plunge pushes the stock near the bear-case implied value of $8, reflecting renewed skepticism about UiPath's ability to convert "agentic automation" narrative into durable enterprise demand amid intensifying bundling competition. While the company's balance sheet remains strong (~$1.4B cash and securities) and buybacks continue, the market is now demanding proof that growth re-acceleration is sustainable, not just a one-quarter beat.

Implication

1. The sell-off likely reflects a miss on key forward indicators (ARR, net-new ARR, NRR) that the previous master report identified as critical; without confirmation of those metrics, the original 'potential buy' thesis is compromised. 2. If NRR fell below 108% or net-new ARR slipped below $40M, the bear case probability rises materially, and the stock may not find support until it prices in sustainable low-teens ARR growth with lower margins. 3. Conversely, if the drop was driven by non-fundamental factors (e.g., broad tech sell-off, profit-taking after run-up) and the underlying metrics actually held, the stock could be oversold near $8, offering a contrarian entry with upside to $12.50–$16. 4. However, the burden of proof now shifts to management: investors should wait for the 10-Q and earnings call transcript to verify whether ARR growth re-accelerated, how net-new ARR trended, and if AI-attach anecdotes translated into larger expansions. 5. Until those data points are confirmed, we downgrade our near-term stance from 'potential buy' to 'hold/watch,' acknowledging that the risk/reward has improved on valuation but deteriorated on fundamentals.

Thesis delta

The prior thesis hinged on ARR growth holding near 12% with NRR≥108% and net-new ARR≥$40M; a 24% post-earnings slide despite a revenue beat suggests one or more of these metrics likely disappointed. This shifts the probability weight from base-case (50%) toward bear-case (25%→40%), lowering conviction from 4 to 3. We now require explicit confirmation of ARR, NRR, and net-new ARR stability before re-endorsing the stock as a buy.